<SEC-DOCUMENT>0001776985-26-000039.txt : 20260601
<SEC-HEADER>0001776985-26-000039.hdr.sgml : 20260601
<ACCEPTANCE-DATETIME>20260601075948
ACCESSION NUMBER:		0001776985-26-000039
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20260601
FILED AS OF DATE:		20260601
DATE AS OF CHANGE:		20260601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		261047255

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190840

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kascopumitamignsclc1.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i4297371a4dac485a8c4ee8761a704ae2_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%">FORM 6-K</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE MONTH OF JUNE 2026</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER 001-39081 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%">BioNTech SE<br></font><font style="color:#333333;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">An der Goldgrube 12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">D-55131 Mainz</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Germany</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">+49 6131-9084-0<br></font><font style="color:#333333;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F&#58; Form 20&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Form 40&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">On May 30, 2026, BioNTech SE and Bristol Myers Squibb Company announced interim Phase 2 data from the global Phase 2&#47;3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer. The press release is attached as Exhibit 99.1.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:125%">BioNTech SE</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Ramon Zapata-Gomez</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Sierk Poetting</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Ramon Zapata-Gomez</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Dr. Sierk Poetting</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Financial Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Operating Officer</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; June 1, 2026</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Description of Exhibit</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">99.1</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline"><a href="a99120260530_bntxascoxpumi.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline">Global Data for BioNTech and Bristol Myers Squibb&#8217;s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial</a></font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a99120260530_bntxascoxpumi.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ib72cb9fcf06b46ea86cddb2d133537ce_1"></div><div style="min-height:74.16pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:35px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Global Data for BioNTech and Bristol Myers Squibb&#8217;s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#9679;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;padding-left:11.96pt">First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data&#160;showing&#160;encouraging efficacy&#160;in combination with chemotherapy&#160;in&#160;first-line&#160;non-small cell lung cancer&#160;across&#160;PD-L1&#160;expression&#160;levels and subtypes,&#160;highlighting its potential to set a new standard of care</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#9679;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;padding-left:11.96pt">Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#9679;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;padding-left:11.96pt">Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">MAINZ, Germany, and PRINCETON, USA, May 30, 2026 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8211; BioNTech SE (Nasdaq&#58; BNTX, &#8220;BioNTech&#8221;) and Bristol Myers Squibb Company (NYSE&#58; BMY, &#8220;BMS&#8221;) today announced interim Phase 2 data from the global Phase 2&#47;3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (&#8220;NSCLC&#8221;). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level (TPS &#706; 1%, TPS 1 &#8211; 49%, and TPS &#8805; 50%). The data are being presented today as a rapid oral presentation (abstract #8513) at the 2026 American Society of Clinical Oncology (&#8220;ASCO&#8221;) Annual Meeting in Chicago. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8220;Despite significant immuno-oncology advances in the treatment of  non-small cell lung cancer, most advanced diseases relapse on or after a PD-(L)1 checkpoint inhibitor treatment,</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> indicating that targeting this immunologic pathway alone is insufficient to achieve durable responses,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Solange Peters, M.D., Ph.D., Lead Investigator and Director of Oncology at the University Hospital of Lausanne, Switzerland.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> &#8220;I am encouraged by the efficacy signal with this bispecific approach, showing robust responses across subtypes and PD-L1 levels, supporting the continued investigation of pumitamig and its potential to deliver improved outcomes for a broad range of patients with NSCLC.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Phase 2 part of the ROSETTA Lung-02 trial evaluated pumitamig in two dose levels, in combination with chemotherapy. At this interim analysis at the April 13, 2026 data cut-off, among 40 response-evaluable patients with a median follow-up of 9.0 months, pumitamig plus chemotherapy showed a confirmed objective response rate (&#8220;cORR&#8221;) of 57.1% in patients with non-squamous NSCLC and 68.4% with squamous NSCLC with a disease control rate (&#8220;DCR&#8221;) of 100%. Encouraging anti-tumor activity was observed at both dose levels, with higher response rates at the lower dose showing a cORR of 63.6% for non-squamous and 72.7% for squamous NSCLC. Results were high at each PD-L1 expression level (cORR&#58; 47.6% TPS &#706; 1%&#59; 77.8% TPS 1 &#8211; 49 %&#59; 100% TPS &#8805; 50%). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pumitamig plus chemotherapy demonstrated a manageable safety profile with a low discontinuation rate. Grade &#8805; 3 treatment-related adverse events (&#8220;TRAEs&#8221;) were reported in 48.8% of patients and were considered pumitamig-related in 23.3%, leading to treatment discontinuation in four (9.3%) patients. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:35px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Immune-related AEs (&#8220;irAEs&#8221;) occurred in 16 (37.2%) patients and grade &#8805; 3 irAEs in two (4.7%) patients. Bleeding events were reported in nine (20.9%) patients, with only one event being grade 3.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8220;The data we are presenting today provide further evidence of the potential of pumitamig to enhance anti-tumor responses in advanced lung cancer, one of the most challenging indications, by simultaneously targeting PD-L1 and VEGF-A with a single molecule,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Prof. &#214;zlem T&#252;reci, M.D., Co-Founder and Chief Medical Officer at BioNTech</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">. &#8220;Pumitamig has consistently shown efficacy in three global Phase 2 trials across PD-L1 expression levels. Together with our partner BMS, we are continuing to advance pumitamig in ongoing pivotal and novel-novel combination trials with the goal of delivering better outcomes for more patients.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8220;We are committed to advancing the science of lung cancer with pumitamig and improving on the standard of care for people with this challenging disease</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">,&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Anne Kerber, Senior Vice President, Head of Development, Hematology, Oncology, Cell Therapy at Bristol Myers Squibb</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">. &#8220;With one of the broadest registrational programs in the class, we are focused on accelerating the development of pumitamig together with BioNTech, with the goal of delivering meaningful benefit to patients, including those who have been left behind by current therapies.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BioNTech and BMS are&#160;advancing a broad&#160;development plan for pumitamig in non-small cell lung cancer across disease stages and subgroups.&#160;In addition to the ongoing&#160;global ROSETTA Lung-02 trial, which&#160;is currently recruiting&#160;for the Phase 3 part of the trial, there are two&#160;additional&#160;global Phase 3 clinical trials in&#160;NSCLC&#160;currently enrolling. These include&#160;ROSETTA Lung-201&#160;(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NCT07361497</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">), evaluating&#160;pumitamig compared to durvalumab following concurrent chemoradiation therapy in patients with unresectable stage III NSCLC&#59; and ROSETTA Lung-202&#160;(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NCT07361510</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">), evaluating&#160;pumitamig compared to pembrolizumab as a first-line treatment for patients with advanced PD-L1 &#8805; 50% NSCLC. Pumitamig is also being investigated in combination with other novel investigative treatments for NSCLC, including in combination with investigational antibody-drug conjugates (&#8220;ADCs&#8221;) and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">other modalities.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">About ROSETTA Lung-02</font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The global Phase 2&#47;3 ROSETTA Lung-02 trial (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NCT06712316</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">) is evaluating pumitamig (BNT327&#47; BMS986545) in combination with chemotherapy in patients with first-line treatment of non-squamous and squamous non-small cell lung cancer </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">without actionable genomic alterations</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> and with any level of PD-L1 expression. In the Phase 2 dose-optimization part of the trial, patients were randomized 1&#58;1 to 1400 mg or 2000 mg pumitamig plus histology-specific chemotherapy Q3W (non-squamous&#58; carboplatin + pemetrexed&#59; squamous&#58; carboplatin + paclitaxel). The primary endpoints of the Phase 2 part of the trial are objective response rate (ORR) per investigator&#8217;s assessment (RECIST 1.1), best percentage change in tumor size from baseline, and safety. Key secondary endpoints include duration of response (DOR) and disease control rate (DCR). The Phase 3 part of the trial will evaluate pumitamig plus chemotherapy versus pembrolizumab plus chemotherapy. Based on the totality of the data, a pumitamig 1500 mg flat dose Q3W plus chemotherapy was selected for further evaluation in the Phase 3 part. The primary endpoint of the Phase 3 part of the trial is</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">progression free survival (PFS) assessed by blinded independent central review (BICR). Key secondary endpoints include overall survival (OS), ORR, DOR.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">About Pumitamig</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pumitamig is an investigational bispecific immunomodulator, jointly developed by BioNTech and BMS, designed to cooperatively bind to PD-L1 and VEGF-A. It is aimed at restoring the immune system&#8217;s ability to recognize and destroy tumor cells while simultaneously cutting off the blood and oxygen supply that feeds tumor cells (anti-angiogenesis effect), preventing them from growing and proliferating. By anchoring </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:35px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">to PD-L1 receptors on tumor cells, we believe pumitamig localizes VEGF-A blockade within the tumor microenvironment, potentially enhancing antitumor activity while minimizing systemic exposure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">More than 2,000 patients have been treated with pumitamig in clinical trials to date. Seven global Phase 3 trials with registrational potential are currently ongoing, evaluating pumitamig plus chemotherapy compared to standard of care treatments, in first-line small cell lung cancer (ROSETTA LUNG-01, NCT06712355)&#59; first-line non-small cell lung cancer (ROSETTA LUNG-02, NCT06712316)&#59; </font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">unresectable stage III non-small cell lung cancer (ROSETTA Lung-201, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NCT07361497</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">)&#59; first-line advanced PD-L1 &#8805; 50% non-small cell lung cancer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> </font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(ROSETTA Lung-202, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">NCT07361510</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">)&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">first-line triple-negative breast cancer (ROSETTA BREAST-01, NCT07173751)&#59; first-line microsatellite stable colorectal cancer (ROSETTA CRC-203, NCT07221357)&#59; and first-line gastric cancer (ROSETTA GASTRIC-204, NCT07221149). Pumitamig is also being explored in 10+ novel-novel combination trials with ADCs and other novel modalities, with the aim of expanding its role across tumor types and identifying additional pivotal opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">About NSCLC</font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Non-small cell lung cancer (NSCLC) covers all epithelial lung cancers other than small cell lung cancer and includes squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung. It is the most common type of lung cancer, accounting for approximately 85% of cases, and is the leading cause of cancer-related deaths worldwide.</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Scientific advances have transformed the treatment of NSCLC, improving outcomes for many patients. However, NSCLC remains an aggressive disease with a poor prognosis and a 5-year survival rate of 18 to 22% in advanced stages.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> Patients with low levels of PD-L1 expression typically do not respond well to checkpoint inhibitor-based regimens creating a significant unmet need for new treatment options that provide durable responses to a broad range of patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">About BioNTech</font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">For more information, please vis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">it </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline">www.BioNTech.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">BioNTech Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning&#58; BioNTech&#8217;s collaboration with Bristol Myers Squibb (BMS)&#59; BioNTech and BMS&#8217;s ability to successfully co-develop and co-commercialize pumitamig (also known as BNT327 or BMS986545), if approved&#59; the rate and degree of market acceptance of pumitamig, if approved&#59; the initiation, timing, progress, and results of BioNTech&#8217;s research and development programs, including BioNTech&#8217;s current and future clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations, including expectations regarding the potential </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:35px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">indications in which pumitamig may be approved, if at all&#59; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate&#59; and discussions with regulatory agencies. In some cases, forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The forward-looking statements in this press release are based on BioNTech&#8217;s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech&#8217;s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to&#58; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as risks associated with clinical data, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data&#59; the nature of clinical data, which is subject to ongoing peer review, regulatory review and market interpretation&#59; the impact of tariffs and escalations in trade policy&#59; competition related to BioNTech&#8217;s product candidates&#59; the timing of and BioNTech&#8217;s ability to obtain and maintain regulatory approval for its product candidates&#59; BioNTech&#8217;s ability to identify research opportunities and discover and develop investigational medicines&#59; the ability and willingness of BioNTech&#8217;s third-party collaborators to continue research and development activities relating to BioNTech&#8217;s product candidates and investigational medicines&#59; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech&#59; BioNTech&#8217;s and its collaborators&#8217; ability to commercialize and market its product candidates, if approved&#59; BioNTech&#8217;s ability to manage its development and related expenses&#59; regulatory and political developments in the United States and other countries&#59; BioNTech&#8217;s ability to effectively scale its production capabilities and manufacture its products and product candidates&#59; and other factors not known to BioNTech at this time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">You should review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in BioNTech&#8217;s Report on Form 6-K for the period ended March 31, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC&#8217;s website at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">www.sec.gov</font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">About Bristol Myers Squibb&#58; Transforming Patients&#8217; Lives Through Science</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what&#8217;s possible for the future of medicine and the patients we serve. For more information, visit us at&#160;BMS.com&#160;and follow us on&#160;LinkedIn,&#160;X,&#160;YouTube,&#160;Facebook&#160;and&#160;Instagram.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:35px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">current expectations and projections about Bristol Myers Squibb&#8217;s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to the collaboration with BioNTech may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated, that future study results may not be consistent with the results to date, that pumitamig (also known as BNT327 or BMS986545) alone or in combination with chemotherapy may not achieve its primary study endpoint or receive regulatory approval for the indications described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether pumitamig alone or in combination with chemotherapy will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb&#8217;s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb&#8217;s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by Bristol Myers Squibb&#8217;s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CONTACTS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"><br></font><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">BioNTech</font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Media Relations</font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Jasmina Alatovic</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Media&#64;biontech.de</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Investor Relations</font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Douglas Maffei, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Investors&#64;biontech.de</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Bristol Myers Squibb</font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Media Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">media&#64;bms.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#181010;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">investor.relations&#64;bms.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1. Mariniello A et al. BioDrugs</font><font style="color:#005ea2;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">,</font><font style="color:#1b1b1b;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2025 Feb 15&#59;39(2)&#58;215&#8211;235. </font></div><div><font style="color:#1b1b1b;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2. Lin Z et al. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Medicine (Baltimore). 2025 Jul 25&#59;104(30)&#58;e43300. </font></div><div style="padding-right:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3. Liu SV et al. Immunotherapy.&#160;2025 Oct&#59;17(14)&#58;1005-1013.&#160; </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M[Z,[Z"X%/M28Y_$[NAJG+QSQY-&C$1V&C#ICXD3#&+S%/&O!2>_FYX??YSF
MBO5-4$J^Y]MOY;Q&]EF??BJG0S7>X?W[S1YP7E>N:PV"_FQ08<_8:Z_JE2#A
M@H=K>0Y[F#AZM,F,-G.XX$G5FGKCNG4R2:]!7[ < B6V1U< JE*!%0WSZ0">
MVELUYJC-V=\DRKT=Q2\U\V!<#(/#VXB HD8,&"!Q7W]MHO1 !1:- @I7:)[;
M,("/CQX\V%PS096(@@ B3@H 3BH01^J]^H<*7:XCXF]4[EZCH"#JC%,C\SY&
M8QUD091L#1M+YJ$Q 3 M)7/K..@'^SJF-<+!??L,>([H-15*A:8KP-$# '.E
M0)V2]6Y8L\88]^*Y<V:MO*;K]:P3YYXZ?GPX^! 4J!/(@@0%U@)0V"N=/O1G
M=31%:QGN-43K&>[M)SCO8-W;^;-G.T1F.EX VF8&NF  %WWS<XG:?-2@03)5
M]\<ZV#="$$07=.Y<X?=1JF> C] )PVXX/UTS"QX ,U[W0;W,,\B.T&6"$AG%
M@@<] ##V2A!B+ZQMRKAQ4E=;&^[,25MTQ\PZ@*<FMUK2WE+P_#I1BK<4]EK-
MPR:@&OQ."B7=QJU>+6/4^>FX64<C>F/0T:IT%'-.N?6#TM+GW38'/%S/[\/4
MV3$LOV-(^"N?7[MJE8E6O'<P1-NRG(R"@HE".$;2Z=/AY[,6# U0H4>Q9![
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MZU8#4K?F<<&#DQ&! 2BUDBO3-)+388+GQYIY<!H: F1!2R^9_9!9R&Z(%SP
M'HI!>]7.+[@/ "1K4#\  !R8+%SO%,M06W2+7M%)&#RZGK,)">V<G,^RKCQ/
MRQYJ1R>MS%,[& ?6;+A*UX&M" KS-0@" K*,6[13/RU6 -*5JZRH^%_1KTX/
M)>U)\. ?14X+&@II.Y[HTLT\V-X5ZAOT16;N6?!L+93:O&JY^+=S<N&OR?(D
M^;'Y,ES:?U(D<U2&-)34R]UU!>'O]S3%0-LP)@Y)#<+/,1I!H52 Q1TL0MMP
M1-[O,.?Q9![3NE9'1>F16MV1P,,S>6_+^O4=BOOUFA%Q5*A;K.!!F M12..\
M&!*# A9 XP>>1PI>Z!?!P68KVMHX"D&$/23\^*/)LNBG72VE 09 0$MP9@L>
M:@HBLBO,2]@77;]8VLO0;3J(<S18X?3<GP!#X+/K19^\1SWB%=K!1/N> @\!
MI39$NZR0C0E 9#VWYJ'#ZQVT0WFG:A;O:JX3,W@8?!9O*Y+B[47RK.R9M+6T
M27G*4_-U!+Z"0 V4\O?S9JY#ERY:\*!4>#6;H<BGF%^O*10:0A?J:6C8QN:'
M*X?U&R!ZP8/Q<#HR$+UZ,D6CI_L4B;9Q#]Z#RGB5"%7!^:%1L=(V&]V(CE!'
MG(O(SM]MQ\H+'HR-?@@JQ:'"G&?C2!9P7,MGUN@]T:-]L6\""#J@P+;@@9)Z
MYQ8X&+0-Q^&^MW)R(D[@_;I>S%WB3YPP%!00\@(0U!ED60IW:ENO0#NAD3T%
M'MA&O:=5S>R/VH< X8*GP#-S0T<P &A>=0PC#W_PY-48\"0I>(HV%W;=*BYO
M-%^$XXMQ=.KR%H2&I&,R8FX8T,K<OFF3<32*>PL>%$N'IC/P((]5F2@6JH!C
M45>AM)OZ=UO$1@(/(#;@V;FS0R&,D?D;7;ON@ >C4Y] #W JG'7>C!EA8WG!
M0R"@V(5& CR3+97"N<8_I&OB[] G:*%]\0PS\5>GXKD6/% TKW-0P^U2.FN;
M+&0GLB1#ZM8NVK2N0'-/'#EB]L :R))TV>BNT0WU"C4I6;.GP$.@\(*'!A%U
M(YU)%SQN)Q"!4B[0+ W0(YT8B;[;=J?6M*F3?ID@!6OR8[H968FFPI7W4DU]
M%"MXC,(TPN*8GR]:U!X\JO"NP(/3$4EH:Z-@"F04AG)M$R(2>.C4V<S3T^#!
ML)MT/=P#YR0X0$-M$>T%CYNM]BB8R1BTH(F.MBM$>Y?HC9[V*X7ROJ!U%,2=
M@0=]X#P<2Z$FQ-FA4Y/'CI4S\?$QG3,$B.C%ZHEY"MTOO\S3T^#QRSR1P%/0
MF^!A.'KUPS0Y\^9IN;4P-_;#>YI]ZO)K#=WK#G@RM:[ Z:$M./K>3L#C;55[
MG8+HA]-"Y3 LSXM4\S#OX#V<R-OCMQVF:&F;M^9A/3@C=1YM8/9S1<%AZS(_
M\-")A+9QAHYBF X5P&L.K8VZ 5K"9W$<[\MVP#H#CZLOG!_'VJU@92W,RKPU
M$HT<SGS1#/ &&'X_KK09'=+H@)("=ML4Z4#;5!=>\%SR@ >;\WY7X*$U[SUA
M0"E@:)M>ZX+'.V]S:5M7)PJZ'I)6-4G&T&N&>F5/SHH(@NY*5^"A]L'!H! 8
M-9;,@\$8<MF:Q3B/1FH*:!3,&3.3>4*9A,&:VQWB/2)5C:=%"Z=G#42S[F0>
M!+K&'(5G&,=T.H=^X,&0.#RU5J)F$<![,3DY##B:#D1OZ)W?Z8B24(NV,_#0
M)J=MZS8+.%%!S4D <_5C=<3[U$_\=P?P**#9'Q23^Y(1N-Y[FH']LB8+GMT:
MG*B7..+C;2R07;L"#Y]U;8:.N!?/( M;\)!5O?,K:!R^P2N63!OQ>$[.S&Q)
M?#/>U#X]_2_DA,$S9XZI45I"@S4,R$90N-FT.F LM V%,5P$="7.A+U%[\U[
M9#(Z0"B(4PNL@6+7'O? Z6A6$.VI*[B?S6!T >DLX1#=!0_[PW X#I3,C=Q^
MX#%-@1]^,-'2#C!=OH[CLP9J"M-:U[6R#[(CUS,S<^<\?N!9L7BQJ<7<T^6L
MBV 1*:,#!M:*/1A4MX6>2R D(.*@T&; 3VL=T'-_ZYBLE;:PVZI&3P1,!LI6
M+\R/T#/WBV;. \6SSP!(M.KY+!G(;54S0[/,@O>9[P!0AO OW*HV[<Y#]\T)
M@Z1?)<C]?:72UMK6X^#!2>F.)24D&&?>H0HBS?939Z%U: ][Q@(>T\7JT\<8
M@5D(62@Q1)>@>';>0%U%L6VXO5((INU0$B@+[Z_4^H),P?<_<"2 0"U$YZZ[
MX.E,(H&'P[(  7VQ#J_SDP'X'/LFZT)YH2"\EQ$Z:=X9>  G^F*F0\" IG'$
MQ@Q)9\_VG?/L#QUZI9[ ^=$]G2UJ,IZ#,UM&@5T!!8T;ZBHZASN4HM'D<%O5
M=W3M/).Z@WJ)P,">L#O@ZPH\]L@0WR_B&=R7PZNS]&_0,G=(BK^@;_:+3Q$\
M $\L)_,[!0\MZ4O_N&"H6_K JU)WMZ['P .WIO4\S//B/3;&V;5L+=[=>@#:
M15O5*\Q?R"@V<I)QB&H8EO-K& 1#8;Q,Y]P4@S[ 9 9]:ARFTX""J(B3TJVS
M7R? N7 \>U(8&DA4XZA0I-/#',7!Z0%F- (](:)[SY2Q'C(QSH$>O+,K,B$4
MT'ZOAI\\=Y-S+@XG0[=,TFL\!S.)[C@]P65@Z'0WSD[PLN<!O<)G^ X2P0.P
M6#T!6&Q!!K#9@P"(C="AO8ZYWBH-/NC8@@>AUL1N!!U^XM38!=OO"<WX  N^
M @"IZ= /)R$6J [P&]; ,_HJ,.EHDH7I&K(>@A]@!)3VZR^\;$W5',59MJC
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1I]4XBAT     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
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MU9\AC+U@B;X I/"[*A(PSS^(%6:YCN5,8SW5' -548*H<[.UY]C-!$@2 E4
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M %U.&2\LEA\O\B$XUW'SK8P+VX5HT Q4%^SLFI>7C7G8^=_H^W-5O7Z][1I
M5!"H D ,A)B=2BT- #"'0!62QVLAT?[;MADUQA*H^EZNP24%8!J$"E5E3-HN
M1$&(0%5H__]O+NOB_0?^FP"6C2EW=LV7VJX!1 .!*@"$1N,#O?NEE@8 >!0"
M54B>&[8V3[D&X" 2J'I#^XDZ!6!:A A5Y8)HFX^"4(&J4#;%"ZK&U,[_5MER
MUTS+\\4+;-< HH! %0!"T]:VJNO/4TL# #P6 E5('J_K<!*H>D$[+*, 3),0
MH6I,XR1DH"JT[7]9^W?+ _]M".OBU]H^1S6#&,8-@2H A$3[PZ[4T@  !R%0
MA>3Q^B$; E4O^-Q&E[&]R@W+TYZ#JA];:,=F-!^G"AVH"K*&:5F;GW?^&\JV
M_7BXG)J7VZX!!(5 %0!"HOUA5VII ("#$*A"\G@-7 A4!T?Z($^Y7?WSXM;F
M*=LT)(IV !_+@X<8 E7AG;OF&OGJOO/?T;8N_J!LBG]]QQV/>[SM'D 0"%0!
M("0^;^(/2"T- ."$0!62AT!U>6,(BKS.*#[@9":O1-FF(6'D6+J/\?#*&+7-
M!B660%4X=_ZZOU9.B]/.?RN V[7YOFJVQKD-P2!0!8!0R*OWKOK%C]32  "7
M@T 5DH= =7GC"%1U9AO*+%C6>LH'&;NNX^S% .>]BY@"5>'N^NB3JMI\K_/?
M"^!.4YQN^_0TVST 50A4 2 46J_[4TL# %P9 E5('EG3QS4 !Y% =5 T%]"7
M8M,V"YG@]5S?9PP/'V(+5(77O.9Q?V&G7O]795U\Q/GOJFM^8GNV]K=M]P#4
M(% %@%!HO>Y/+0T <&4(5"%Y^"C5\H8.B;S.)GZ,O)Z4*UJO_L?P\848 ]4%
MV]/BGU>U^=_.?UO;7?/S=S?%%]BN :A H H (=![W9]:&@#@:A"H0O)X?>V%
M0'50?&[;7H_?MGF3;1(R0XZMZY@/K8Q5VV0P8@Y4A7)J_F%5F__A_/>5+>NB
M.C==^S+;-0#O$*@"0 BTOD5 +0T <'4(5"%YCI_>/.,:@(-(H#HH&J\HQ1"$
M@5\T@OFVC8NVN6#$'J@*VTWQ]\JF..]L0UU35U/S=;9K %XA4 6 $"C50-32
M  !+0* *R>/U%6 "U<'0>MV?)^KY(Z^@N8[]T(8>2RD$JD*U:YY;-F;;V8ZR
M95V\O_WSFVW7 +Q!H H VFA]BX!:&@!@.0A4(6F\!RL$JH.A\452GJB/A_98
M^YN9OG!K\Y1M+@BI!*K"N=G:<[P&3#TL&_-P69M7V*X!>(% %0"TT9B<0"T-
M + \!*J0-+X+"PEM;%-J9!NH>MRNA3Q1'P\REEUC8% #/%#92TJ!JO".IOB\
M]M_^L0-M!='\8?OGJZOJQK]HNP<P* 2J *"-RN0$:FD @*4A4(6D\5Y8!)BA
MEFV@ZGW]U,G,-@4C00)/]U@8QO9<#+J.JM= =;KFY89) LQRU_R4L\T EDUQ
MBE#UZL@Q:_=5-;CMOVN;R(YV^PA4 4 5_Y,3J*4! /I H K)TJTCY#FDD\#6
M-J=&CH'JL=MO-:[^#.FQVR>WV.9@),@L"M=8&-*0#R%2FZ&ZX-[W'7MBV13?
MXVPWA+7YP>VF^.NV>^"@K(N'G/OND+;_;O"/N_F"0!4 M/%]WT,M#0#0#P)5
M2!:-=82D#=N<&GD&JI-;7/T92IE)&#+X@G!X?ZAR>N.$;4J=5 /5!=6N>575
MF \[V]?WOU0/7O<LVS78!X%J?PA4 4 3WY,3J*4! /I#H K)HO&ZK\R"M<VI
MD6.@ZGMI!MEGMBD8&;(LAVM,#&; #U.E'J@*9;W^;653?,C9!V7+QORW[5US
MS'8-]D"@VA\"50#0Q/=$$FII (#^$*A"DFC,3@U56&09J'K<)C'D+$((B_??
M@H ?ILHA4!7:]EY2UN:_'^A#".MBYUR]_N6V:V A4.T/@2H :.)_<@*U- !
M7PA4(3DD%#Q^>O.B:] -::BO7&89J'I^+9M7E,:-S_$EOS6V&75R"50%::]J
MS /.OBA;UL7N3FU>:+L&+02J_2%0!0!-?$].H)8& .@/@2HD1?<A*L\%16?
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MA..&TY.9:QP,:<C7WPA4XZ+:-5]7-:9Q[D]ER]K<M],47VV[=F@(5/M#H H
MVGB]Y[%22T,.$*B"%@2JD#P2>KK&R2 2J Z&1A$H 9MM#C)G#+.>"53CHZS7
MOWR[+G:<^U39LBE^96?7?*/MVJ$@4.T/@2H :./UGN>2U-*0/@2JH 6!*B2/
MK''H&B>#2* Z&#I%H#Q9O]78)B%CQG!30: :)SM-\05E;7[!N5^5+1OS6^V?
M_\QV;64(5/M#H H VGB]Y]DCM32D#H$J:$&@"LGC=1U% M7!\'J<]AK@F($N
M[3'V/CNU,^ 'J00"U7BISA]Y5KL??^+ ?@U@61>_7]7KWVZ[MA($JOTA4 4
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M0+4_!*H $ KM-[Y$:FE("0)5T() %9*G'0_^9CP2J Z.%($^?W@NI\QDMEV
M1)#QJCU6Y/H2RZMM!*II4]7KU[?[^N<.[/L EK7Y8#4U+[-=.P"!:G\(5 $@
M)'*/XJIC?$HM#:E H I:$*A"\O@,( E4_:#YM?^]<@%,AVYF:H#@7<:F[4)P
M"%33Y^RNN::LS8\[CX&R$FZ6T^*5MFN/@4"U/P2J !"2$&]\B=32D ($JJ %
M@2HD33?;T>?KP 2J7@CQJM)"+H+Q$RQ,;8WI:[8$JGE0O>?:SVKW^=:!8Q#
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MN/?>9SZQ/3[?7=;%GQ\X9@E*H+JB!*H L"+M?41TRVA=SJZOU-+@ 0)5T()
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M-L5WEHWYJ',<>)9 =44)5!&C=8RUM" S5KFWQY4D4(6,(5#%[)V',NE\N(9
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LU+.NXX41V!XC>SC5(% %+?S=RV\^\O\!4\.*#/(<'7P     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
